Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL) has engaged Fortrea (NASDAQ: FTRE) as the contract research organisation for management of the IND opening p
– 45 mg once daily oral dose selected for Phase 3 –– Results support trial expansion to lower age group and study will now include adolescents ages 10-17 years –– If positive, pre-planned interim analysis at Week 48 may